The Trendlines Group Investor presentation

Steve Rhodes
Chairman and CEO

Todd Dollinger Chairman and CEO Haim Brosh Chief Financial Officer

August 2020



Legal disclaimer

Important notice

This presentation is for informational purposes only and does not constitute or form any part of any offer for sale or subscription of, or solicitation of, any offer to buy or subscribe for any securities of The Trendlines Group Ltd. ("Company") or any of its portfolio companies nor shall it or any part of it form the basis of, or be relied on in connection with, any contract, commitment or any investment decision whatsoever in Singapore, Israel, the United States or in any other jurisdiction. The summary information herein does not purport to be complete. The information in this presentation should not be relied upon as any representation or warranty, express or implied, of the Company. No reliance should be placed on the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. The information is subject to change without notice.

The past performance of the Company is not necessarily indicative of its future performance. This presentation may contain statements that constitute forward-looking statements which involve risks and uncertainties. These statements include descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the results of business operations and financial condition, industry, environment and future events and plans of the Company. Such forward-looking statements are not guarantees of future results, performance or achievements. Actual results, performance or achievements of the Company may differ from those expressed in the forward-looking statements as a result of various factors and assumptions, such as known and unknown risks and uncertainties, including those risk factors discussed in our Offer Document dated 16 November 2015 and in our other filings with the SGXNET. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future. In light of these risks and uncertainties, actual events, results and developments could differ materially from those expressed or implied by the forward-looking statements. Reliance should not be placed on these forward-looking statements, which reflect the view of the Company or its officers as of the date of this presentation only. The Company does not undertake any obligation to update or revise any of the forward-looking statements, whether as a result of new information, future events or otherwise.

None of the Company or any of its respective affiliates, advisers or representatives shall have any liability whatsoever for any loss howsoever arising, whether directly or indirectly, from any use, reliance or distribution of this presentation or its contents or otherwise arising in connection with this presentation.

Neither this presentation nor any of its contents may be used without the prior written consent of the Company.



Trendlines: building companies, creating value, impacting people

Trendlines invests in medical and agrifood companies to transform industries and create value for all.







Trendlines' investment arms













Trendlines Agrifood – Israel

- Agrifood incubator
- Licensed by Israel Innovation Authority

Trendlines Agrifood Innovation Centre – Singapore

- · Agrifood incubator and accelerator
- Supported by Enterprise Singapore

Trendlines Medical – Israel

- Medical incubator
- Licensed by Israel Innovation Authority

Trendlines Medical Singapore

- Medical incubator
- Supported by Enterprise Singapore

Trendlines Medical Shanghai - China

Supported by the Chinese Government

Trendlines Labs – Israel – Singapore – China

- Global in-house innovation centers
- Invent technologies to develop products and companies
- 10 technologies invented & developed for our incubators

No. of portfolio companies

Agrifood

Medical





25

11



Trendlines' venture funds







Trendlines Agrifood Fund Pte. Ltd.

- · Singapore-based, agrifood tech fund
- Committed capital US\$23 million; Fund target US\$40 million
- Established 2019

Bayer Trendlines Ag Innovation Fund L.P.

- US\$10 million fund
- 3 of 5 investments completed
- Established 2016

Maryland/Israel Trendlines Fund

- Fully invested
- 2011

Portfolio







Portfolio








Exits







Portfolio value expansion





Exits: estimated returns and IRR

Exit	Company/Description	Acquirer	Estimated Return*	IRR (%)
2020	ApiFix	OrthoPediatrics Corp.	15 X	37
2017	MitrAssist	Wai Tech (Hong Kong) Holding Ltd.	2.1 X	12
2017	BioSight	Arkin Bio Ventures LP	216.7 X	71
2016	E.T.View Medical	Ambu A/S	1.2 X	5
2014	Stimatix GI	B. Braun SAS	47.9 X **	70
2014	Inspiro Medical	OPKO Health	8.8 X	131
2013	InnoLap Surgical	Teleflex, Inc.	3.2 X	447
2013	FlowSense Medical	Baxter Int'l	4.0 X	280
2011	PolyTouch Medical	Covidien Ltd.	6.7 X	289
Weighted	Average		8.4X	83%


Notes



^{*} Estimated return represents the multiple of exit proceeds over Trendlines' investment in the exited company, which includes (i) our cash investment and (ii) estimated value of services provided to the exited company.


^{**} Exit by Stimatix GI asset sale to B. Braun. Based on the fair value of Stimatix GI (which remains in our portfolio) as of 30 June 2020 compared to our investment at that time.

Carrying value on eve of exit vs. exit value




^{*}Includes present value of Stimatix GI estimated royalties; not including earnout from ApiFix exit.





Trendlines' model: hands-on support





Trendlines' model: strategic partnerships





Trendlines' investment record

55 Current companies

15 revenue stage

36 follow-on funding

33 clinical or field trials

44 technology proven

9 exits

IRR*

83%

ROI*

8.4X

*Weighted average IRR and ROI



Management team



Todd Dollinger Chairman & CEO



Steve Rhodes
Chairman & CEO



Haim Brosh CFO & Joint Co. Sec'y.



Barak Singer
CEO Trendlines Incubators
Israel



Nitza Kardish, Ph.D.
CEO Trendlines Agrifood
Fund




Eric Loh
CEO Trendlines Medical
Singapore



Nir Goldenberg
CEO Trendlines Labs



Companies* achieving milestones to create value



^{*55} portfolio companies as at 30 June 2020; 37 written-off portfolio companies not included; exited companies on the right



10 most valuable portfolio companies

Fair market value of 10 most valuable portfolio companies ~US\$52.5 million, 59% of total portfolio value of ~US\$88.5 million.*

Company name	Initial investment	% owned (fully diluted)
Arcuro Medical Ltd.	2013	21.10
BioFishency Ltd.	2013	30.93
ElastiMed	2015	33.07
Fidmi Medical Ltd.	2014	47.85
Hargol FoodTech Ltd.	2016	21.90
Leviticus Cardio Ltd.	2010	19.42
OrthoSpin Ltd.	2014	25.83
Saturas Ltd.	2013	21.74
Stimatix GI Ltd.	2009	27.16
STS Medical Ltd.	2013	28.43

^{*}As at 30 June 2020, not including the fair value of investments in consolidated portfolio companies. Companies listed alphabetically.



Minimally invasive scoliosis treatment system

Minimally invasive non-fusion surgical system for treating progressive adolescent idiopathic scoliosis

Achievements

- Sales in Canada, Europe, Israel, Asia, U.S.
- Completed >360 successful surgical procedures
- First patients >7 years post-surgery
- Offices in Israel and U.S.
- Received FDA; CE mark

Acquired by





The ApiFix minimally invasive scoliosis treatment system









2011 Founded **2020** Exited



Investors Trendlines, B. Braun








Nanobody-based biological insect control

Developing new types of biological solutions for insect control that utilize novel nanobody technology to uniquely target the insect gut

Achievements

- Proven POC in target insect testing and plant data
- Selected highly active leads for optimization and development



New biological solutions for insect control utilizing ecofriendly nanobody technology









Founded 2017



Co-Founder & CTO
Rony Oren Benaroya,
PhD



IP Provisional patent submitted



Funding ~US\$2.2 million



Investors Bayer
Trendlines Ag
Innovation Fund



Our Board Member Nitza Kardish, PhD





Remote early detection of pests & diseases in field crops

Integrates external data collected by drones (together with AI software, deep learning and computer vision) to accurately and autonomously detect, identify, and monitor diseases, pests, and other agronomic problems in field crops.

Achievements

- 2020: Initiated sales in Israel, North America
 South America
- 2020: Chosen as one of StartUs Insights top five deep learning startups impacting agriculture
- 2019: Shortlisted for Poland Prize Season, #3 acceleration program



AgroScout's first target is the potato market, the 4th most important crop globally









Founded 2017



CEO Simcha Shore



IP Provisional patent submitted



Funding ~US\$4 million



Investors Trendlines, Kibbutz Yiron, Agriline, Private investors



Our Board Members
Sarai Kemp,
Steve Rhodes






Novel system for meniscus repair


An all-suture, knotless meniscus repair system

Achievements

- Initial sales in the United States
- FDA and CE regulatory approvals
- Distributors in the US; LATAM and APAC countries



















Founded 2013



CEO Lee Ranon



IP U.S. and Chinese patents



Funding ~US\$6.6 million



Investors Strategic and Private investors, surgeons



Our Board Members Todd Dollinger, **Barak Singer**










Digital dialysis clinic

A technological solution that provides patients with end stage renal dialysis the option of athome, user-friendly peritoneal dialysis.

Achievements

- Successful FIH clinical study
- Completed alpha product



Lightweight system enables ESRD patients to perform PD anywhere, anytime









Founded 2016



CEO Hezkiah Tsoory



Funding ~US\$2.6 million, €2.2 million Horizon 2020 grant



Our Board Members Steve Rhodes, **Barak Singer**







Smart external fixation with real-time feedback

A smart external fixation system that allows realtime physician follow-up and reduces dependency on patient compliance

Achievements

- Successful FIH in US and Israel
- Received FDA clearance



The OrthoSpin strut and control box are part of a smart external fixation system









Founded 2014



CEO Oren Cohen Chair Assaf Dekel, MD



IP 1 National phase (U.S., EU, China); 1 provisional



Funding US\$7.9 million



Investors Trendlines, J&J Innovation



Our Board Members Todd Dollinger, Barak Singer









Precision irrigation system

Advanced decision support system for optimal irrigation through a miniature sensor embedded in the trunks of trees, vines, and plants

Achievements

- 2020: Sales in California, Spain, Israel, Italy and China
- Installed ~500 sensors in 3 experimental/10 commercial farms (California, Spain, Israel)
- Established strategic cooperation with Netafim and NaanDanJain



Saturas represents an advanced decision support system for optimal irrigation









2013



CEO Anat Halgoa Solomon



Funding US\$8.2 million investment round; Horizon 2020 grant for €1.5 million



Investors


Trendlines, Gefen Capital, Hubei Forbon Technology Co, Private investors



Our Board Members Todd Dollinger, **Steve Rhodes**










Key value components



Portfolio decrease includes ApiFix removal from portfolio due to exit; and proceeds are added to receivables.

^{***} Deferred taxes from unrealized portfolio company valuation profits are offset and paid only upon realization of cash from exits.



^{**} Israeli government loans are nonrecourse, and which only come due upon exit events.

Stock overview

Trendlines' SGX share price movement: Aug 2019 - Aug 2020 (S\$)



On chart, 1,2,3 refer to publication dates of Trendlines' financial events.

As at 6 Aug 2020	SGX: 42T S\$	OTCQX: TRNLY US\$
Share price	S\$ 0.111	US\$ 3.88
IPO price	S\$ 0.33	_
52-wk high	S\$ 0.138	US\$ 4.5
52-wk low	S\$ 0.054	US\$ 2.33
Market cap	S\$ 87.82 million	US\$ 61.39 million
Shares outstanding	791.2 million	Each OTCQX ADR = 50 SGX shares
Net asset value per share/ADR*	S\$ 0.17	US\$ 6.0



^{*}Net asset value as at 30.06.2020; NAV in S\$ based on exchange rate of S\$ 1.37 = US\$ 1.00

Stock performance: Net Asset Value (NAV)

	SGD	USD
NAV per share/ADR*	S\$ 0.17	US\$ 6.0
Price per share/ADR**	S\$ 0.111	US\$ 3.88
% discount to NAV	34%	29%

^{*}As at 30 June 2020



^{**}Market close as at 6 Aug 2020

Looking ahead



Our quality of life is inextricably linked to our health and our food. More than ever, we believe that our investment focus on medical and agrifood sectors has the potential to impact people's lives and provides a significant opportunity in value creation for our stakeholders.



Creating and developing companies to improve the human condition

SGX: 42T

OTCQX: TRNLY

+972.72.260.7000 www.trendlines.com









Steve Rhodes, Chairman & CEO steve@trendlines.com

Todd Dollinger, Chairman & CEO todd@trendlines.com

Haim Brosh, Chief Financial Officer haim@trendlines.com